双介入法治疗原发性肝癌疗效的临床研究  

Clinical Study on Efficacy of Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation in Treating Hepatocellular Carcinoma

作　　者：钱智玲[1] 崔世昌[1] 王海燕[1] 

机构地区：[1]首都医科大学附属北京佑安医院肝五科,北京100069

出　　处：《中国普外基础与临床杂志》2008年第9期686-689,共4页Chinese Journal of Bases and Clinics In General Surgery

摘　　要：目的评价双介入方法治疗原发性肝癌的临床应用价值。方法选择2004年3月至2006年3月期间在我院进行介入治疗的原发性肝癌患者137例,其中行单纯性肝动脉化疗栓塞87例(TACE组),行肝动脉化疗栓塞和经皮肝穿多弹头射频消融双介入治疗50例(双介入组)。全部病例定期做CT复查和AFP测定,观察肿瘤的客观疗效。结果TACE组肿瘤客观有效率(CR+PR)为34.5%,AFP下降幅度54.2%,2年生存率为43.7%;双介入组客观有效率为70.0%,AFP下降幅度78.0%,2年生存率为62.0%,2组间差异均有统计学意义(P<0.05)。结论双介入方法治疗原发性肝癌疗效肯定,优于单纯应用TACE治疗。Objective To evaluate the efficacy of transcatheter arterial chemoembolization （TACE） combined with radiofrequency ablation （RFA） in treating primary hepatocellular carcinoma （HCC）. Methods From March 2004 to March 2006, 137 patients with primary HCC underwent TACE alone （n=87） and TACE＋RFA （n=50）, respectively, after the interventional treatment, all patients periodically received CT reexaminations and alpha fetoprotein （AFP） measurement. The therapeutic efficacy, AFP level and survival rate between two groups were compared with each other. Results In TACE group the effective rate （CR＋PR） was 34.5%, AFP decreasing amplitude was 54.2% , and 2 years survival rate was 43.7%. While in TACE＋RFA group, the effective rate （CR＋PR） was 70.0%, AFP decreasing amplitude was 78.0%, and 2 years survival rate was 62.0%, there were significant differences between two groups （P〈0.05）. Conclusion Combined application of TACE and RFA is significantly superior to TACE alone in treatment of primary HCC.

关 键 词：原发性肝癌 栓塞治疗 多弹头射频 

分 类 号：R735.7[医药卫生—肿瘤]